News >

FDA Panel Backs Blinatumomab for MRD+ ALL

Jason Harris
Published: Wednesday, Mar 07, 2018

David M. Reese, MD

David M. Reese, MD
Blinatumomab (Blincyto) received an 8 to 4 vote from the FDA’s Oncologic Drugs Advisory Committee (ODAC) in favor of an indication for the treatment of minimal residual disease (MRD)-positive B-cell precursor acute lymphoblastic leukemia (ALL).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication